Gland Pharma Ltd
Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. We operate primarily under a business to business (B2B) model and have an excellent track record in the development, manufacturing and marketing of complex injectables. This presence across the value chain has helped us witness exponential growth. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major.
- Market Cap ₹ 21,117 Cr.
- Current Price ₹ 1,282
- High / Low ₹ 3,559 / 1,130
- Stock P/E 21.5
- Book Value ₹ 464
- Dividend Yield 0.00 %
- ROCE 24.8 %
- ROE 18.5 %
- Face Value ₹ 1.00
Pros
- Company is almost debt free.
- Company has delivered good profit growth of 23.9% CAGR over last 5 years
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
468 | 527 | 755 | 991 | 994 | 1,348 | 1,479 | 1,620 | 2,044 | 2,633 | 3,463 | 4,401 | 3,934 | |
356 | 394 | 519 | 630 | 678 | 845 | 854 | 1,085 | 1,338 | 1,678 | 2,161 | 2,890 | 2,736 | |
Operating Profit | 112 | 133 | 236 | 361 | 316 | 502 | 625 | 535 | 706 | 955 | 1,302 | 1,511 | 1,198 |
OPM % | 24% | 25% | 31% | 36% | 32% | 37% | 42% | 33% | 35% | 36% | 38% | 34% | 30% |
0 | 14 | 5 | 9 | 30 | 37 | 34 | 49 | 66 | 139 | 135 | 224 | 267 | |
Interest | 0 | 3 | 13 | 13 | 17 | 16 | 6 | 4 | 4 | 7 | 3 | 5 | 7 |
Depreciation | 0 | 11 | 15 | 28 | 57 | 63 | 74 | 78 | 82 | 95 | 99 | 110 | 140 |
Profit before tax | 112 | 133 | 213 | 327 | 272 | 459 | 578 | 502 | 686 | 993 | 1,335 | 1,619 | 1,317 |
Tax % | 22% | 24% | 26% | 32% | 23% | 32% | 28% | 36% | 34% | 22% | 25% | 25% | |
Net Profit | 87 | 101 | 158 | 224 | 209 | 314 | 414 | 321 | 452 | 773 | 997 | 1,212 | 983 |
EPS in Rs | 74.07 | 86.09 | 134.45 | 190.40 | 133.53 | 202.40 | 267.01 | 207.24 | 291.65 | 49.88 | 60.94 | 73.78 | 59.72 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 24% |
5 Years: | 24% |
3 Years: | 29% |
TTM: | -6% |
Compounded Profit Growth | |
---|---|
10 Years: | 28% |
5 Years: | 24% |
3 Years: | 38% |
TTM: | -17% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
1 Year: | -60% |
Return on Equity | |
---|---|
10 Years: | 20% |
5 Years: | 19% |
3 Years: | 20% |
Last Year: | 19% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
12 | 12 | 12 | 12 | 16 | 15 | 16 | 16 | 16 | 16 | 16 | 16 | 16 | |
Reserves | 339 | 440 | 598 | 822 | 1,379 | 1,662 | 2,074 | 2,395 | 2,847 | 3,631 | 5,887 | 7,142 | 7,633 |
62 | 84 | 123 | 176 | 166 | 117 | 6 | 6 | 5 | 5 | 5 | 5 | 5 | |
170 | 182 | 187 | 277 | 197 | 292 | 378 | 512 | 655 | 435 | 588 | 671 | 963 | |
Total Liabilities | 582 | 718 | 920 | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,617 |
168 | 206 | 309 | 460 | 649 | 788 | 872 | 843 | 929 | 968 | 954 | 1,502 | 1,566 | |
CWIP | 66 | 143 | 202 | 208 | 192 | 202 | 161 | 199 | 123 | 188 | 338 | 191 | 125 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 163 | 8 |
348 | 369 | 409 | 619 | 917 | 1,096 | 1,441 | 1,887 | 2,471 | 2,929 | 5,203 | 5,978 | 6,918 | |
Total Assets | 582 | 718 | 920 | 1,287 | 1,758 | 2,086 | 2,474 | 2,928 | 3,523 | 4,086 | 6,496 | 7,834 | 8,617 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
220 | 476 | 202 | 185 | 701 | 605 | 791 | ||||||
-12 | -100 | -359 | -319 | -761 | -1,521 | -1,007 | ||||||
-93 | -116 | -4 | -3 | -7 | 1,238 | 35 | ||||||
Net Cash Flow | 115 | 260 | -160 | -136 | -67 | 322 | -181 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 58 | 64 | 62 | 62 | 62 | 95 | 103 | 107 | 90 | 83 | 71 | 99 |
Inventory Days | 230 | 169 | 229 | 283 | 248 | 271 | 283 | 388 | 250 | 312 | 205 | |
Days Payable | 68 | 57 | 74 | 58 | 60 | 136 | 161 | 190 | 82 | 97 | 80 | |
Cash Conversion Cycle | 58 | 225 | 174 | 217 | 288 | 283 | 239 | 229 | 289 | 251 | 286 | 225 |
Working Capital Days | 103 | 84 | 70 | 100 | 141 | 155 | 154 | 185 | 191 | 161 | 169 | 168 |
ROCE % | 29% | 36% | 39% | 22% | 28% | 30% | 22% | 27% | 30% | 28% | 25% |
Documents
Announcements
- Closure of Trading Window 17h
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 21 Mar
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17 Mar
- Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 13 Mar
- Scrutinizer''s Report On Postal Ballot 9 Mar
Concalls
-
Jan 2023Transcript PPT
-
Nov 2022Transcript PPT
-
Oct 2022TranscriptNotesPPT
-
Jul 2022Transcript PPT
-
May 2022Transcript PPT
-
Jan 2022Transcript PPT
-
Nov 2021Transcript PPT
-
Sep 2021Transcript PPT
-
Jul 2021TranscriptNotesPPT
-
May 2021Transcript PPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
Revenue breakup
Gland Pharma is primarily a contract manufacturer of injectables, with B2B segment generating ~95% of revenues in FY22 [1]
As of Q3FY22, Glands key markets continue to remain MENA, LATAM and APAC & Core markets, namely US, Canada, Europe, Australia and New Zealand accounted for 70% of the revenue, similar to the contribution in Q3 FY '22. India market accounts for 9% of our Q3FY23 revenue.[2]
As of FY2022, Exports contribution to the revenue of the Company is approximately 80.30%. Gland exports to almost 60 countries across 6 continents [3]